Actuate Therapeutics (ACTU) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Indexes:

Not included

Description:

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Events Calendar

Earnings

Next earnings date:

Nov 29, 2024

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with ACTU included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development
ACTU
globenewswire.com29 October 2024

CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in “ Webinar Wednesday ” hosted by Lantern Pharma on October 30, 2024.

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
ACTU
globenewswire.com09 September 2024

CHICAGO and FORT WORTH, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- – Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), provided an update on its Phase 1/2 trial of elraglusib in relapsed/refractory Ewing Sarcoma (r/r EWS).

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline
U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline
U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline
ACTU
seekingalpha.com17 August 2024

This week was another slow week for pricings, with two companies making their public debut, along with three SPACs. On the filing side, offshore-focused drilling equipment and aftermarket service provider, HMH Holding, filed to raise $100 million. Three IPOs are currently scheduled to list in the week ahead, all based in the Asia Pacific region. One SPAC is also expected to price.

FAQ

  • What is the primary business of Actuate Therapeutics?
  • What is the ticker symbol for Actuate Therapeutics?
  • Does Actuate Therapeutics pay dividends?
  • What sector is Actuate Therapeutics in?
  • What industry is Actuate Therapeutics in?
  • What country is Actuate Therapeutics based in?
  • Is Actuate Therapeutics in the S&P 500?
  • Is Actuate Therapeutics in the NASDAQ 100?
  • Is Actuate Therapeutics in the Dow Jones?
  • When does Actuate Therapeutics report earnings?

What is the primary business of Actuate Therapeutics?

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

What is the ticker symbol for Actuate Therapeutics?

The ticker symbol for Actuate Therapeutics is NASDAQ:ACTU

Does Actuate Therapeutics pay dividends?

No, Actuate Therapeutics does not pay dividends

What sector is Actuate Therapeutics in?

Actuate Therapeutics is in the Healthcare sector

What industry is Actuate Therapeutics in?

Actuate Therapeutics is in the Biotechnology industry

What country is Actuate Therapeutics based in?

Actuate Therapeutics is headquartered in United States

Is Actuate Therapeutics in the S&P 500?

No, Actuate Therapeutics is not included in the S&P 500 index

Is Actuate Therapeutics in the NASDAQ 100?

No, Actuate Therapeutics is not included in the NASDAQ 100 index

Is Actuate Therapeutics in the Dow Jones?

No, Actuate Therapeutics is not included in the Dow Jones index

When does Actuate Therapeutics report earnings?

The next expected earnings date for Actuate Therapeutics is 29 November 2024